Skip to main content
Rheum to Breathe Banner

Multi-omics, biomarkers, rheumatoid arthritis and pulmonary fibrosis

Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear. A team from Taizhou Hospital in Zhejiang Province

Read Article
Interstitial lung disease is a group of conditions that cause inflammation and scarring in the lungs. This JAMA Patient Page describes types and causes of interstitial lung disease as well as its diagnosis, treatment, and prognosis. https://t.co/WELKKR0SX7 https://t.co/ykzR16ja3L
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/ugbmKlXsBp
Dr. John Cush @RheumNow( View Tweet )
LIVE September 9th, 7PM EST Join Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator, as they review ACR & EULAR #ILD guidelines. Where are we now? Where are we going? Don’t miss it! https://t.co/PVo0dbQLCn #Rheumatology #ILD https://t.co/gp1qfeEt3S
Dr. John Cush @RheumNow( View Tweet )

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease

Rheumatoid arthritis interstitial lung disease (RA-ILD) represents a major therapeutic evidence void in our current treatment paradigm. RA-ILD is common, with clinically significant disease seen in 8% of patients. In the past RA-ILD was frequently under-diagnosed, leading to identification of a

Read Article
MUC5 mutations not in SSc-ILD. Study of 2363 SSc-ILD, 3526 SSc w/o ILD & 15076 controls. They found no assoc w/ MUC5B promoter variant & SSc-ILD. (Suggesting ILD pathogenic mechanisms differ between RA and SSc) https://t.co/bBq52X0Mwq https://t.co/eu1IpaXGL8
Dr. John Cush @RheumNow( View Tweet )
×